PTC Therapeutics' (PTCT) Translarna Receives EMA Conditional Marketing Renewal
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Credit Suisse Upgrades PTC Therapeutics (PTCT) to Outperform; ROW Translarna Sales Risk Off the Table
November 14, 2016 6:18 AM ESTCredit Suisse upgraded PTC Therapeutics (NASDAQ: PTCT) from Neutral to Outperform with a price target of $25.00 (from $15.00), saying they believe much of the near-term risk associated with ROW Translarna sales are off the table.
Analyst Alethia Young commented, "PTC announced this morning that CHMP is... More
PTC Therapeutics' (PTCT) Price Target Raised to $13 at RBC Capital
November 11, 2016 12:57 PM ESTRBC Capital maintained a Sector Perform rating on PTC Therapeutics (NASDAQ: PTCT) and raised its price target to $13.00 (from $5.00). Earlier CHMP recommended the renewal of the conditional marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients five years and older.
Commenting on developments, Simos Simeonidis said, "We had assigned a 50% chance that Translarna would be pulled, given its failure on the... More
PTC Therapeutics (PTCT) Surges After CHMP Recommends Renewal of Translarna Marketing Authorization
November 11, 2016 7:24 AM ESTPTC Therapeutics (NASDAQ: PTCT) surges 82% in pre-open trade after the company announced that the Committee for Medicinal... More